William Hill, Institute Fellow at The University of Manchester & CRUK Manchester Institute, shared on LinkedIn:
“Really cool paper in Nature Medicine identifying Tu-stroma, an extracellular vesicle lncRNA, as a blood-based biomarker for the early detection of ovarian cancer.
It isnt just a great diagnostic performance (AUC 0.99 vs CA125’s 0.59 for picking up STIC, the pre-invasive precursor), it’s the biology.
Tu-stroma isn’t a tumour-burden-proportional signal that scales with disease stage. It’s an EV-associated Flower-Win/Lose cell competition signal, actively remodelling the fitness of neighbouring host cells to favour tumour expansion. It’s already elevated at the precursor lesion and stays flat across stages, because it reflects the initiating biology, not the tumour mass.
Signals of cell competition as clinically actionable early detection biomarkers!
Understanding the biology of the earliest stages of cancer gives us rational, biologically-informed biomarkers that can actually pick up disease before it becomes disease.”
Title: Blood-based RNA biomarker for the early detection of ovarian cancer
Authors: Jochen Wilhelm, Amit Kumar, Hitesh Vasiyani, Narsimha Mamidi, Zhaoyu Sun, Aenya Gogna, Praveen Bhoopathi, Keshav Gogna, Chelsea Salyer, Amy Lu, Kranthi Kumar Chougoni, Ava Gardner, Andrew Poklepovic, Masaki Nagane, Kumari Shree, Emad Rakha, Karuppaiyah Selvendiran, George Maxwell, Jamie Bakkum-Gamez, Shariska Petersen Harrington, Elnaz Abbasi Farid, Nadia Traficante, David Bowtell, Christopher Collier, Esha Madan
Read the Full Article.
Other articles about ovarian cancer on OncoDaily.